X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Lupin Ltd with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs MYLAN (US) - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN   MYLAN
EQUITY SHARE DATA
    LUPIN
Mar-19
MYLAN
Dec-18
LUPIN/
MYLAN
5-Yr Chart
Click to enlarge
High Rs9863,276-   
Low Rs7201,803-   
Sales per share (Unadj.) Rs369.51,507.4-  
Earnings per share (Unadj.) Rs13.440.9-  
Cash flow per share (Unadj.) Rs37.4323.2-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs303.71,630.7-  
Shares outstanding (eoy) m452.49514.50-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.31.7 137.1%   
Avg P/E ratio x63.662.0 102.6%  
P/CF ratio (eoy) x22.87.9 290.4%  
Price / Book Value ratio x2.81.6 180.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m386,0641,306,551 29.5%   
No. of employees `00017.735.0 50.5%   
Total wages/salary Rs m31,5130-   
Avg. sales/employee Rs Th9,453.822,158.1 42.7%   
Avg. wages/employee Rs Th1,782.00-   
Avg. net profit/employee Rs Th343.0601.7 57.0%   
INCOME DATA
Net Sales Rs m167,182775,533 21.6%  
Other income Rs m3,6400-   
Total revenues Rs m170,822775,533 22.0%   
Gross profit Rs m28,822200,679 14.4%  
Depreciation Rs m10,850145,210 7.5%   
Interest Rs m3,07837,300 8.3%   
Profit before tax Rs m18,53418,168 102.0%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,017-2,890 -312.0%   
Profit after tax Rs m6,06621,059 28.8%  
Gross profit margin %17.225.9 66.6%  
Effective tax rate %48.7-15.9 -305.8%   
Net profit margin %3.62.7 133.6%  
BALANCE SHEET DATA
Current assets Rs m138,536433,057 32.0%   
Current liabilities Rs m61,299315,746 19.4%   
Net working cap to sales %46.215.1 305.4%  
Current ratio x2.31.4 164.8%  
Inventory Days Days8484 100.2%  
Debtors Days Days11293 120.5%  
Net fixed assets Rs m127,516150,441 84.8%   
Share capital Rs m905413 219.2%   
"Free" reserves Rs m136,5170-   
Net worth Rs m137,422838,985 16.4%   
Long term debt Rs m66,417905,534 7.3%   
Total assets Rs m279,4942,250,483 12.4%  
Interest coverage x7.01.5 472.1%   
Debt to equity ratio x0.51.1 44.8%  
Sales to assets ratio x0.60.3 173.6%   
Return on assets %3.32.6 126.2%  
Return on equity %4.42.5 175.8%  
Return on capital %8.93.2 280.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m37,1320-   
CASH FLOW
From Operations Rs m16,660161,156 10.3%  
From Investments Rs m-32,825-83,300 39.4%  
From Financial Activity Rs m7,441-75,076 -9.9%  
Net Cashflow Rs m-8,7241,335 -653.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.82 Rs / USD

Compare LUPIN With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare LUPIN With: AJANTA PHARMA  SUVEN LIFESCIENCES  PANACEA BIOTECH  VENUS REMEDIES  AUROBINDO PHARMA  



Today's Market

Indian Indices Witness Selling, HDFC Q1FY20 Results, and Top Cues in Focus Today(Pre-Open)

India share markets ended their day deep in the red yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 305 points (down 0.8%).

Related Views On News

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock (Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Here's What to Do with Falling Small Cap Stocks (Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

7 Stocks to Profit From an Irreversible Trend (The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock (The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Jul 22, 2019 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS